Maravai LifeSciences Holdings, Inc. (MRVI) stock
MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.28−0.12 (-1.62%)
Close on Nov 17, 2026Market cap $1.89BP/E –Yield –
Maravai LifeSciences r&d expenses
Research and development expenses are spending on new products and technology.
Maravai LifeSciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $15.22M, down 20.0% year over year. For fiscal 2025 it was $17.40M, down 9.5% from the year before. The highest annual figure on record is $19.22M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.40M | -9.5% |
| FY2024 | Dec 31, 2024 | $19.22M | +11.2% |
| FY2023 | Dec 31, 2023 | $17.28M | -5.9% |
| FY2022 | Dec 31, 2022 | $18.37M | +20.7% |
| FY2021 | Dec 31, 2021 | $15.22M | +63.6% |
| FY2020 | Dec 31, 2020 | $9.30M | +156.5% |
| FY2019 | Dec 31, 2019 | $3.63M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.70M | -24.2% |
| Q1 FY2026 | Mar 31, 2026 | $3.89M | -20.4% |
| Q4 FY2025 | Dec 31, 2025 | $3.79M | -16.9% |
| Q3 FY2025 | Sep 30, 2025 | $3.84M | -18.3% |
| Q2 FY2025 | Jun 30, 2025 | $4.88M | -0.9% |
| Q1 FY2025 | Mar 31, 2025 | $4.89M | -2.9% |
| Q4 FY2024 | Dec 31, 2024 | $4.56M | -0.7% |
| Q3 FY2024 | Sep 30, 2024 | $4.70M | +8.2% |
| Q2 FY2024 | Jun 30, 2024 | $4.92M | +17.4% |
| Q1 FY2024 | Mar 31, 2024 | $5.03M | +21.4% |
| Q4 FY2023 | Dec 31, 2023 | $4.59M | -8.3% |
| Q3 FY2023 | Sep 30, 2023 | $4.35M | -19.3% |
| Q2 FY2023 | Jun 30, 2023 | $4.19M | -1.9% |
| Q1 FY2023 | Mar 31, 2023 | $4.15M | +12.2% |
| Q4 FY2022 | Dec 31, 2022 | $5.01M | -45.4% |
| Q3 FY2022 | Sep 30, 2022 | $5.39M | +176.9% |
| Q2 FY2022 | Jun 30, 2022 | $4.27M | +121.6% |
| Q1 FY2022 | Mar 31, 2022 | $3.70M | +71.1% |
| Q4 FY2021 | Dec 31, 2021 | $9.18M | +339.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.95M | +4.2% |
| Q2 FY2021 | Jun 30, 2021 | $1.93M | +20.6% |
| Q1 FY2021 | Mar 31, 2021 | $2.16M | -42.3% |
| Q4 FY2020 | Dec 31, 2020 | $2.09M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.87M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.60M | – |
| Q1 FY2020 | Mar 31, 2020 | $3.74M | – |
See a number that looks wrong?